Novo Nordisk (NJ) Receives Subpoena in the U.S.
Published: Feb 16, 2011
At this time, Novo Nordisk cannot determine or predict the outcome of this matter or assess the consequences thereof. In addition, the company cannot predict how long the investigation will take or when it will be able to provide additional information.
Read the full announcement in PDF format: http://hugin.info/2013/R/1489420/424931.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
Further information: Media: Rachel Curtis Graversen Tel: (+45) 4442 7603 Email Contact In North America: Ken Inchausti Tel: (+1) 609 786 8316 Email Contact Investors: Klaus Bulow Davidsen Tel: (+45) 4442 3176 Email Contact Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 Email Contact Jannick Lindegaard Tel: (+45) 4442 4765 Email Contact In North America Hans Rommer Tel: (+1) 609 919 7937 Email Contact